About

Eurospital was established in 1948 in Trieste, and today, after surpassing the milestone of 75 years, it continues to look towards the future by pursuing those “Innovations for Better Living” that embody its corporate vision. Firmly rooted in the Italian territory but also active internationally through various collaborations, Eurospital is now present in over 50 countries through a well-established network of distributors.

Eurospital is a family-owned company with over 20 years of experience in designing, manufacturing, and commercialising diagnostic tests for the quantitative determination of calprotectin, based on the method originally developed by Prof. Fagerhol (University of Oslo, Norway) in 1992. The Calprest® diagnostic kit was the first ELISA test to receive FDA certification for the quantitative detection of faecal calprotectin and is still considered the international “Gold Standard” for the differential diagnosis of patients with chronic inflammatory bowel diseases.

The EGL Line

From pioneers in calprotectin determination, the new EGL – Eurospital Gastrointestinal Line was born and has since evolved to provide comprehensive solutions for the identification of gastrointestinal diseases.
The EGL line offers a complete panel of diagnostic solutions with IVD products for the quantitative determination of several biological markers, such as calprotectin, pancreatic elastase, and faecal haemoglobin. For the quantification of each marker, a variety of solutions is available: rapid tests, ELISA tests, and turbidimetric tests, which, through the use of different technologies, meet all laboratory needs, from small to large diagnostic routines.
Recently introduced, rapid tests for the therapeutic monitoring of biological drugs used in the treatment of chronic intestinal inflammation, such as Crohn’s disease or ulcerative colitis as a complement the EGL Line’s offering.

Our Vision

We have always stood by the side of clinicians and laboratorians to improve patients’ quality of life through technological and scientific innovation applied to in-vitro diagnostics.
Every day, we renew our commitment to enhance our solutions to support the diagnosis of gastrointestinal diseases through the passionate work of our R&D team, Production and Quality Department, and our technical-scientific and specialised support team.

We never tire of listening to our customers: their experiences and needs are a constant source of innovation and improvement.
The principle that inspires us? Lead by Perfection.

Quality and Continuous Improvement

The Human Health sector, in which we operate, requires the highest commitment in terms of quality of the product and the services offered, in addition to staff training to ensure peace of mind and safety. Our commitment has been recognised since 1995 with the Eurospital Quality Management System Certification for all business sectors according to European and international standards.

Today, Eurospital is certified in compliance with the UNI EN ISO 9001:2015 and EN ISO 13485:2016 standards, and also within the MDSAP (Medical Device Single Audit Program).

To further strengthen our commitment to meeting the highest European and international standards, in April 2022, Eurospital became one of the first Italian companies to adapt to the new In-Vitro Diagnostic Regulation and obtain the “EU Quality Management System Certificate (IVDR)” for in-vitro medical diagnostic devices from the international body TÜV SÜD.